{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:13:25Z","timestamp":1771341205139,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01944-4","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T11:37:27Z","timestamp":1767699447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CBX2 promotes cisplatin resistance in ovarian cancer via SIAH2-mediated \u03b2-catenin stabilization and ATG9B-dependent autophagy activation"],"prefix":"10.1186","volume":"19","author":[{"given":"Xinxin","family":"Kou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanjing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1944_CR1","first-page":"32","volume":"4","author":"MA Shihab","year":"2024","unstructured":"Shihab MA, Daim NE, Ovarian, Cancer. East J Agricultural Biol Sci. 2024;4:32\u201342.","journal-title":"East J Agricultural Biol Sci"},{"key":"1944_CR2","unstructured":"Institute NC. SEER*Explorer: an interactive website for SEER cancer statistics. 2025. Available from: https:\/\/seer.cancer.gov\/explorer\/."},{"key":"1944_CR3","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.3390\/ijms26104611","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz B, Biernacka K, \u0141ukasiewicz H, Samulak D, Piekarska E, Romanowicz H, Makowska M. Ovarian Cancer\u2014Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen receptors\u2019 molecular backgrounds. Int J Mol Sci. 2025;26:4611.","journal-title":"Int J Mol Sci"},{"key":"1944_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/cancers16040807","volume":"16","author":"R Strippoli","year":"2024","unstructured":"Strippoli R, Niayesh-Mehr R, Adelipour M, Khosravi A, Cordani M, Zarrabi A, Allameh A. Contribution of autophagy to epithelial mesenchymal transition induction during cancer progression. Cancers. 2024;16:807.","journal-title":"Cancers"},{"key":"1944_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13148-025-01852-w","volume":"17","author":"W Su","year":"2025","unstructured":"Su W, Wang W, Zhang G, Yang L. Epigenetic regulatory protein chromobox family regulates multiple signalling pathways and mechanisms in cancer. Clin Epigenetics. 2025;17:48.","journal-title":"Clin Epigenetics"},{"key":"1944_CR6","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2004-08-3367","volume":"106","author":"Y Katoh-Fukui","year":"2005","unstructured":"Katoh-Fukui Y, Owaki A, Toyama Y, Kusaka M, Shinohara Y, Maekawa M, Toshimori K. Morohashi K-i. Mouse polycomb M33 is required for Splenic vascular and adrenal gland formation through regulating Ad4BP\/SF1 expression. Blood. 2005;106:1612\u201320.","journal-title":"Blood"},{"key":"1944_CR7","doi-asserted-by":"publisher","first-page":"16552","DOI":"10.1038\/s41598-019-53006-7","volume":"9","author":"P Sproll","year":"2019","unstructured":"Sproll P, Eid W, Biason-Lauber A. CBX2-dependent transcriptional landscape: implications for human sex development and its defects. Sci Rep. 2019;9:16552.","journal-title":"Sci Rep"},{"key":"1944_CR8","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.7150\/jca.44475","volume":"11","author":"Y Xu","year":"2020","unstructured":"Xu Y, Pan S, Song Y, Pan C, Chen C, Zhu X. The prognostic value of the chromobox family in human ovarian cancer. J Cancer. 2020;11:5198\u2013209.","journal-title":"J Cancer"},{"key":"1944_CR9","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1038\/s41388-024-03151-9","volume":"43","author":"J Chen","year":"2024","unstructured":"Chen J, Shan W, Jia Q, Chen Y, Jiang W, Tian Y, Huang X, Li X, Wang Z, Xia B. USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2. Oncogene. 2024;43:3170\u201383.","journal-title":"Oncogene"},{"key":"1944_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41389-018-0103-1","volume":"7","author":"LJ Wheeler","year":"2018","unstructured":"Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K, Bitler BG. CBX2 identified as driver of Anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 2018;7:92.","journal-title":"Oncogenesis"},{"key":"1944_CR11","doi-asserted-by":"crossref","unstructured":"Dou Y, Chen F, Lu Y, Qiu H, Zhang H. Effects of Wnt\/\u03b2-catenin signal pathway regulated by miR-342-5p targeting CBX2 on proliferation, metastasis and invasion of ovarian cancer cells. Cancer Manage Res. 2020;12:3783\u201394.","DOI":"10.2147\/CMAR.S250208"},{"key":"1944_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1080\/14728222.2019.1627329","volume":"23","author":"M Jangal","year":"2019","unstructured":"Jangal M, Lebeau B, Witcher M. Beyond EZH2: is the polycomb protein CBX2 an emerging target for anti-cancer therapy? Expert Opin Ther Targets. 2019;23:565\u201378.","journal-title":"Expert Opin Ther Targets"},{"key":"1944_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-021-00888-9","volume":"14","author":"J Zhu","year":"2021","unstructured":"Zhu J, Luo J-e, Chen Y, Wu Q. Circ_0061140 knockdown inhibits tumorigenesis and improves PTX sensitivity by regulating miR-136\/CBX2 axis in ovarian cancer. J Ovarian Res. 2021;14:1\u201312.","journal-title":"J Ovarian Res"},{"key":"1944_CR14","first-page":"1668","volume":"11","author":"S Zheng","year":"2019","unstructured":"Zheng S, Lv P, Su J, Miao K, Xu H, Li M. Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K\/AKT signaling pathway. Am J Translational Res. 2019;11:1668.","journal-title":"Am J Translational Res"},{"key":"1944_CR15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/1878-0261.12894","volume":"15","author":"MA Iqbal","year":"2021","unstructured":"Iqbal MA, Siddiqui S, Ur Rehman A, Siddiqui FA, Singh P, Kumar B, Saluja D. Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. Mol Oncol. 2021;15:1450\u201365.","journal-title":"Mol Oncol"},{"key":"1944_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1124\/mol.106.024729","volume":"70","author":"S Park","year":"2006","unstructured":"Park S, Gwak J, Cho M, Song T, Won J, Kim D-E, Shin J-G, Oh S. Hexachlorophene inhibits Wnt\/\u03b2-catenin pathway by promoting Siah-mediated \u03b2-catenin degradation. Mol Pharmacol. 2006;70:960\u20136.","journal-title":"Mol Pharmacol"},{"key":"1944_CR17","doi-asserted-by":"publisher","first-page":"113513","DOI":"10.1016\/j.yexcr.2023.113513","volume":"426","author":"Z Xu","year":"2023","unstructured":"Xu Z, Wu Y, Yang M, Wei H, Pu J. CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote Glycolysis in hepatocellular carcinoma. Exp Cell Res. 2023;426:113513.","journal-title":"Exp Cell Res"},{"key":"1944_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41419-018-1263-9","volume":"10","author":"J Yu","year":"2019","unstructured":"Yu J, Liu D, Sun X, Yang K, Yao J, Cheng C, Wang C, Zheng J. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt\/\u03b2-catenin signaling via transactivation of GSK-3\u03b2 and Axin2 expression. Cell Death Disease. 2019;10:26.","journal-title":"Cell Death Disease"},{"key":"1944_CR19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3892\/etm.2023.12261","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang Y, Song Y, Liu Z, Li J, Wang G, Pan H, Zheng Z. miR\u2013149\u20133p suppresses the proliferation and metastasis of glioma cells by targeting the CBX2\/Wnt\/\u03b2\u2013catenin pathway. Experimental Therapeutic Med. 2023;26:562.","journal-title":"Experimental Therapeutic Med"},{"key":"1944_CR20","doi-asserted-by":"crossref","unstructured":"Lorzadeh S, Kohan L, Ghavami S, Azarpira NJ, B e B. A-M C R. Autophagy and the Wnt signaling pathway: a focus on Wnt\/\u03b2-catenin signaling. Biochim Biophys Acta Mol Cell Res. 2021;1868:118926.","DOI":"10.1016\/j.bbamcr.2020.118926"},{"key":"1944_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/MCB.01082-08","volume":"29","author":"EY Chan","year":"2009","unstructured":"Chan EY, Longatti A, McKnight NC, Tooze SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. Mol Cell Biology. 2009;29:157\u201371.","journal-title":"Mol Cell Biology"},{"key":"1944_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/15548627.2023.2275905","volume":"20","author":"GN Chiduza","year":"2024","unstructured":"Chiduza GN, Garza-Garcia A, Almacellas E, De Tito S, Pye VE, van Vliet AR, Cherepanov P, Tooze SA. ATG9B is a tissue-specific homotrimeric lipid scramblase that can compensate for ATG9A. Autophagy. 2024;20:557\u201376.","journal-title":"Autophagy"},{"key":"1944_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1080\/15548627.2018.1477382","volume":"14","author":"C Ungermann","year":"2018","unstructured":"Ungermann C, Reggiori F. Atg9 proteins, not so different after all. Autophagy. 2018;14:1456\u20139.","journal-title":"Autophagy"},{"key":"1944_CR24","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1038\/s41418-021-00813-z","volume":"28","author":"Y Zhong","year":"2021","unstructured":"Zhong Y, Long T, Gu C-S, Tang J-Y, Gao L-F, Zhu J-X, Hu Z-Y, Wang X, Ma Y-D, Ding Y-Q. MYH9-dependent polarization of ATG9B promotes colorectal cancer metastasis by accelerating focal adhesion assembly. Cell Death Differ. 2021;28:3251\u201369.","journal-title":"Cell Death Differ"},{"key":"1944_CR25","doi-asserted-by":"crossref","unstructured":"Ranasinghe R, Mathai ML, Zulli A. Cisplatin for cancer therapy and overcoming chemoresistance, Heliyon. 2022;8.","DOI":"10.1016\/j.heliyon.2022.e10608"},{"key":"1944_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/medicina59030544","volume":"59","author":"A Havasi","year":"2023","unstructured":"Havasi A, Cainap SS, Havasi AT, Cainap C. Ovarian cancer\u2014insights into platinum resistance and overcoming it. Medicina. 2023;59:544.","journal-title":"Medicina"},{"key":"1944_CR27","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.3390\/ijms24087585","volume":"24","author":"A Zo\u0144","year":"2023","unstructured":"Zo\u0144 A, Bednarek I. Cisplatin in ovarian cancer treatment\u2014known limitations in therapy force new solutions. Int J Mol Sci. 2023;24:7585.","journal-title":"Int J Mol Sci"},{"key":"1944_CR28","first-page":"304","volume":"5","author":"M Ortiz","year":"2022","unstructured":"Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022;5:304.","journal-title":"Cancer Drug Resist"},{"key":"1944_CR29","doi-asserted-by":"publisher","first-page":"153303382110458","DOI":"10.1177\/15330338211045831","volume":"20","author":"L Wang","year":"2021","unstructured":"Wang L, Ren B, Zhuang H, Zhong Y, Nan Y. CBX2 induces glioma cell proliferation and invasion through the Akt\/PI3K pathway. Technol Cancer Res Treat. 2021;20:15330338211045831.","journal-title":"Technol Cancer Res Treat"},{"key":"1944_CR30","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.7150\/jca.92633","volume":"15","author":"R Sun","year":"2024","unstructured":"Sun R, Tu X, Chan S, Wang X, Ji Y, Wang Z, Yu Z, Zuo X, Zhang Q, Chen J. CBX2 deletion suppresses growth and metastasis of colorectal cancer by Mettl3-p38\/ERK MAPK signalling pathway. J Cancer. 2024;15:2123.","journal-title":"J Cancer"},{"key":"1944_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/mmr.2020.11776","volume":"23","author":"M Zeng","year":"2021","unstructured":"Zeng M, Li B, Yang L, Guan Q. CBX2 depletion inhibits the proliferation, invasion and migration of gastric cancer cells by inactivating the YAP\/\u03b2-catenin pathway. Mol Med Rep. 2021;23:137.","journal-title":"Mol Med Rep"},{"key":"1944_CR32","doi-asserted-by":"crossref","unstructured":"Li W, Shi R, Gao Y, Wang X, Shen T, Liu X, Wu Q, Xu X, Wang Z, Du S. CBX2 promotes cervical cancer cell proliferation and resistance to DNA-damaging treatment via maintaining cancer stemness. J Biol Chem. 2025;301:108170.","DOI":"10.1016\/j.jbc.2025.108170"},{"key":"1944_CR33","doi-asserted-by":"publisher","first-page":"216659","DOI":"10.1016\/j.canlet.2024.216659","volume":"587","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu L, Tian Y, Gu M, Wang Y, Ashrafizadeh M, Aref AR, Ca\u00f1adas I, Klionsky DJ, Goel A. Autophagy-driven regulation of cisplatin response in human cancers: exploring molecular and cell death dynamics. Cancer Lett. 2024;587:216659.","journal-title":"Cancer Lett"},{"key":"1944_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3389\/fonc.2020.01037","volume":"10","author":"C P\u00e9rez-Plasencia","year":"2020","unstructured":"P\u00e9rez-Plasencia C, L\u00f3pez-Urrutia E, Garc\u00eda-Castillo V, Trujano-Camacho S, L\u00f3pez-Camarillo C, Campos-Parra AD. Interplay between autophagy and Wnt\/\u03b2-catenin signaling in cancer: therapeutic potential through drug repositioning. Front Oncol. 2020;10:1037.","journal-title":"Front Oncol"},{"key":"1944_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41417-022-00574-y","volume":"30","author":"Z Song","year":"2023","unstructured":"Song Z, Liao C, Yao L, Xu X, Shen X, Tian S, Wang S, Xing F. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt\/\u03b2-catenin signaling and autophagy via targeting HMGA2. Cancer Gene Ther. 2023;30:596\u2013607.","journal-title":"Cancer Gene Ther"},{"key":"1944_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbrc.2023.04.008","volume":"661","author":"J He","year":"2023","unstructured":"He J, Chen J, Shen J. Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma. Biochem Biophys Res Commun. 2023;661:75\u201381.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01944-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01944-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:26:36Z","timestamp":1771338396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01944-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1944"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01944-4","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}